About Nova Vita Laboratories | Leaders in Regenerative Medicine Research

Nova Vita Labs is developing breakthrough cellular therapies, harnessing nature's own messaging system. Currently, we are using on exosomes and peptides as components for innovative treatments for aesthetics, recovery, and systemic inflammation.

Our Approach:
We produce highly concentrated, FDA-compliant exosome and peptide formulas with patented laboratory processes. Our research process follows the full therapeutic journey from proteomics to human outcomes to validate the value of our work.

Our Partnerships:
We collaborate with leading clinical researchers and medical service organizations to validate and advance our therapies. This network of partnerships ensures our research translates into real-world therapeutic solutions.

Our Impact:
Through outcome data collection and analysis, we transform cellular science into practical medical treatment protocols. Our commitment to tracking outcomes, from molecular interaction to clinical results, drives the development of more effective therapeutic solutions.

Our executive team brings together physicians, researsch scientists, and industry veterans with extensive experience in biotech, regulatory compliance, and clinical research.
‍
Our diverse expertise enables us to bridge the gap between scientific innovation and clinical application.

Together, we share a commitment to advancing cellular therapies through rigorous research, innovative technology, and measurable clinical outcomes.

David Crane M.D.

Founder - CEO & CMO

Trillitye R Paullin, Ph.D

Chief Science Officer

Troy Openshaw

Founder - Chief Operations Officer

Tracy Yourke

Founder - Chief Commercial Officer

Dan Pepock

Founder - President

Brock Byers

National Sales Manager

Our Laboratory - Safety and Practice

Our laboratory facility is strategically located in the Alexandria Laboratories campus within the Raleigh-Durham Research Triangle, to optimizes both research capabilities and distribution efficiency.

Operating as an FDA-registered facility with cGMP compliance and ISO class 3 certification, our laboratory maintains the highest standards for therapeutic development.

Each production batch undergoes comprehensive quality testing, including full serology, endotoxin, and microbiological testing according to FDA standards.
‍

USP <62> Testing for microorganism detection for lot release

USP <71> Sterility testing is used for lot release verification

USP <85> LAL kinetic endotoxin testing is used for lot release verification

About Nova Vita Labs

Our Team

Our Laboratory - Safety and Practice